InvestorsHub Logo
Followers 62
Posts 7557
Boards Moderated 1
Alias Born 01/02/2003

Re: None

Thursday, 10/27/2022 11:53:29 AM

Thursday, October 27, 2022 11:53:29 AM

Post# of 426487
There were many good points that KM mentioned at the Q3 C.C. about Amarin's improved financial picture...

However, there were several things of interest that were not mentioned by KM...
-no mention of Denner
-no mention of MND-2119 as a solo drug or in a fixed dose combo with a statin
-no mention of the patented gelatin capsule of Vascepa as a preventative of oxidation of EPA.
-no mention of upcoming reports on the Respect and Mitigate studies - -no mention of the Brave study
- no mention of studies for other anti-inflammatory indications for Vascepa.

IMO some of these unmentioned issues would be better handled by a BP.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News